QIAGEN Focuses New HPV Test Ad Campaign on Real-Life Story of Woman's Escape From Cervical Cancer

GERMANTOWN, Md., April 10 /PRNewswire/ -- Jodi McKinney, mother of five and wife of nearly 20 years, was recently diagnosed with cervical disease. Fortunately, she was able to be treated before it became cervical cancer -- thanks in part to her physician's decision to order an HPV test along with her Pap. Despite her initially normal Pap smear, the HPV test found that Jodi had a high-risk type of the human papillomavirus -- the primary cause of cervical cancer. Now, Jodi, her entire family and her physician are the focus of a new television campaign launched by QIAGEN to share what Jodi learned about cervical cancer prevention with other women across America. QIAGEN is the developer of the digene(R) HPV Test, the only FDA-approved test for HPV.

(Photo: http://www.newscom.com/cgi-bin/prnh/20080410/AQTH092)

View the entire TV ad featuring Jodi McKinney and her family sharing the message about the importance of HPV testing: http://tinyurl.com/4owquc

The ad tells of the scare first experienced by Jodi, her husband Patrick and her five children, and of the happy ending that has allowed Jodi to tell her story today. It is now being broadcast in selected cities across the country. The TV ad can be viewed online as well.

About QIAGEN:

QIAGEN NV is the leading global provider of sample and assay technologies, with its global headquarters in the Netherlands. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue, and assays make these isolated molecules visible to facilitate such vital activities as biological research and detection of disease. QIAGEN has developed and markets more than 500 products as well as instruments that make their use more efficient and accurate. The company provides its products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. QIAGEN's assay technologies include one of the broadest panels of molecular diagnostic tests available worldwide, including the only FDA-approved test for human papillomavirus (HPV), the primary cause of cervical cancer. QIAGEN employs more than 2,600 people in over 30 locations worldwide. Further information about QIAGEN can be found at http://www.qiagen.com.

RELATED LINKS:

To view this release in social media format, go to: http://www.prxbuilder.com/link.aspx?p=638

Information on the protection provided by the HPV vaccine -- http://tinyurl.com/53r2ed

Jodi McKinney's and Dr. Mamie Bowers' video testimonials -- http://tinyurl.com/4qqwsc

NPWH survey of women's knowledge of cervical cancer prevention -- http://tinyurl.com/3pzb8v

SOURCE QIAGEN

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.